SAN FRANCISCO - Eight studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2016 Genitourinary Cancers Symposium, taking place January 7-9 at the Moscone West Building in San Francisco. These notable abstracts investigate several approaches to the treatment and management of prostate cancer and the use of immune checkpoint blockade therapies in patients with metastatic urothelial cancer.

Experts in genitourinary cancers are available on-site to comment on the studies below.

Abstract 1:
**NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.**

Oral Abstract Session A: Prostate Cancer
Thursday, January 7, 2016: 1:00 PM - 1:10 PM PST
Moscone West, Level 2, Ballroom
Durham, North Carolina

Abstract 2:
**Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016).**

Oral Abstract Session A: Prostate Cancer
Thursday, January 7, 2016: 1:10 PM – 1:20 PM PST
Moscone West, Level 2, Ballroom
London, United Kingdom

Abstract 106:
**Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.**
Abstract 196:

The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).

Poster Session A: Prostate Cancer
Thursday, January 7, 2016: 11:30 AM – 1:00 PM PST
Thursday, January 7, 2016: 5:15 PM – 6:45 PM PST
Moscone West, Level 1, West Hall, Poster E22

Jeffrey Karnes, MD
Mayo Clinic
Rochester, Minnesota

Abstract 236:

Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC).

Poster Session A: Prostate Cancer
Thursday, January 7, 2016: 11:30 AM – 1:00 PM PST
Thursday, January 7, 2016: 5:15 PM – 6:45 PM PST
Moscone West, Level 1, West Hall, Poster H11

Lauren Christine Harshman, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Abstract 286:

Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa).

Poster Session A: Prostate Cancer
Thursday, January 7, 2016: 11:30 AM – 1:00 PM PST
Thursday, January 7, 2016: 5:15 PM – 6:45 PM PST
Moscone West, Level 1, West Hall, Poster K7

Michael Thomas Schweizer, MD
University of Washington/Fred Hutchinson Cancer Research Center
Seattle, Washington

Abstract 357:

Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.

Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Friday, January 8, 2016: 1:55 PM – 2:05 PM PST
Moscone West, Level 2, Ballroom

Matt D. Galsky, MD
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Abstract 367:

Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Friday, January 8, 2016: 12:15 PM – 1:45 PM PST
Friday, January 8, 2016: 6:00 PM – 7:00 PM PST
Moscone West, Level 1, West Hall, Poster F2

Andrea B. Apolo
Genitourinary Malignancies Branch, Center for Cancer Research,
National Cancer Institute, National Institutes of Health
Boston, Massachusetts

2016 Genitourinary Cancers Symposium News Planning Team
Sumanta Pal, MD, American Society of Clinical Oncology (ASCO); Daniel A. Hamstra, MD, PhD, American Society for Radiation Oncology (ASTRO); Badrinath R. Konety, MD, MBA, Society of Urologic Oncology (SUO).

View the disclosures for the News Planning Team.

ATTRIBUTION TO THE 2016 GENITOURINARY CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.